peptides clearly begins in the cytosol, it is uncertain whether all processing events occur in the cytosol, or whether peptides can be trimmed once they have been exported into the secretory compartment.
To study the proteolytic processing of antigenic peptides in the secretory pathway, we used the TAP-deficient cell line T2 (9, 10) . T2 cells present cytosolic peptides to TcDs+ at low or undetectable levels. The presentation defect can, however, be bypassed by appending a hydrophobic NH~.-terminal signal sequence to target peptides to the ER (11) . Such peptides are presumably liberated from their NH2-terminal signal through the action of signal peptidase. Signal peptidase is intimately associated with the proteinacious channel used to convey signal-containing proteins to the ElL, and it is believed to act cotranslocationally (reviewed in reference 12).
The dependence of peptide association with class I molecules in T2 cells on signal sequence targeting of peptides enables examination of proteolytic events that occur exclusively in the secretory pathway. We previously demonstrated that mouse TCDS + specific for viral peptides can lyse T2 cells coinfected with recombinant vaccinia viruses (rVV) expressing mouse class I molecules and antigenic peptides routed to the ER via NH2-terminal signal sequences (13, 14) . In this paper, we use this system to examine the ef~ciency with which viral peptides are generated in the secretory pathway from rVVencoded polypeptides consisting of an NH2-terminal signal sequence followed by "tandem peptides" composed of residues 52-59 from vesicular stomatitis virus nucleocapsid protein (N) (designated Pl, restricted by K b) (15) and residues 147-155 from influenza virus nucleoprotein (NP) (designated P2 restricted by K d) (16) . The biochemical nature and intracellular site of proteolytic generation of the P2 determinant were determined by HPLC analysis of acid-soluble peptides associated with K d, as well as a form of K d retained in the ER by replacement of its cytosolic tail with that of adenovirus E3/19K glycoprotein (17).
(PR8) was grown in 10-d-old embryonated chicken eggs and used as infectious allantoic fluid. VSV Indiana strain was grown in baby hamster kidney cells and used as a cell-free supernatant, rVV were grown in thymidine kinase-deficient human 143B osteosarcoma cells. Construction of rW expressing full-length influenza NP (18) , VSV N-protein (19) , H-2K b (14) , H-2K a (14), and ER-retained H-2K a (EC1sK a) (17) have been described. For simplicity and clarity in this paper, the signal sequence of the E3/19K glycoprorein of adenovirus 5, denoted as ES in our previous publications, has been replaced with S denoting the signal sequence 9 In construction of rVV expressing nontargeted minigenes, an initiation Met (M) precedes each minigene product. Recombinant VV expressing N52-s9 residues (M-P1 and S-P1), and NP147qss residues (M-P2, S-Pz) have also been described (13, 14) . rVVs containing tandem T cell determinants were constructed in a manner similar to that described (13, 14) . Briefly, synthetic oligonucleotides containing the appropriate nucleotide sequences were inserted into modified pSCll or modified pSCll containing the adenovirus 5 E3/19K signal sequence 9 Ligation of DNA encoding PjPz or P~PI into the NotI sites of the modified pSCll plasmid resulted in the insertion of an additional Ala between S and the first class I determinant (14) . Construction of PiP2 included an initiating M codon (M-PIP2). The fidelity of genetic engineering procedures was confirmed by DNA sequence analysis of plasmid inserts. Genes were inserted into the TK locus of VV by homologous recombination as described (20) .
Cytolytic Y Cell (CTL) Assay. Target cells (2 x 106) were infected with rVV (2 x 107 PFU) for 1 h in BSS/BSA followed by an additional 3-h incubation in IMDM. Cells were subsequently labeled with NaSlCrO4 (10 #Ci) for 1 h at 37~ and were extensively washed in IMDM. Radiolabeled target cells were suspended in IMDM and incubated with NP-or VSV-specific TcDs+ cells generated from splenocytes primed with rVV expressing either NP (originally termed V69) (21) Peptide Extraction. T2 cells (109) were infected with rVV-S-PIP2
and either VV-K a-or VV-EClsK a. Single rVV infections of rVV-S-PiP2 and rVV-EClsK a were controlled for by coinfection with wild-type VV. Cells were infected at a multiplicity of infection of 10 for 1 h in BSS/BSA, and were then incubated for 15 h at 37~ in IMEM medium supplemented with 7.5% FBS (vol/vol). Peptides were extracted from T2 cells as described (16, 17) , with the exception that cellular material <3,000 kD was collected by passing extracts through filters (Macrosep; Filtron Technology Corp., Northborough, MA) (3,000 kD cut-off). One fifth of the acid extract was resuspended in H20, vacuum dried, resuspended in 300/zl PBS, and assayed directly as described below. The remaining extract was separated by reverse-phase HPLC (Waters 600; Waters 80-effector specificity EiP2 Chromatography Division, Milford, MA), as described (16, 17) . Fractions were vacuum dried and resuspended in 300/zl PBS. NP peptide antigenic activity was detected in the S1Cr release assay by incubating threefold dilutions of each chromatographed fraction with 51Cr-labeled P815 target cells preincubated overnight at 26~ to increase the expression of peptide binding MHC chss I molecules. Cells were labeled at 26~ with NaSlCrO4, and were incubated with peptide for 1 h at 26~ before the addition of H-2a-restricted, NP-specific splenic effector cells at an effector/target ratio of 20:1. Effector and target cells were incubated at 37~ for 7-8 h and harvested as described above.
Results

Presentation of ER-targeted Tandem Peptides. Minigenes ex-
pressing peptide precursors of 17 residues were constructed from two class I-binding peptides, Ns2-s7 (P1) and NP147-15s (P2) arranged head-to-tail in both orientations, preceded by the adenovirus 5 E3/19K signal sequence (S) as shown in Table 1 and as described in the Materials and Methods. rVV were generated to express the tandem peptides, S-P1P2, S-P2P, and also M-P1P2. The latter peptide lacks a signal sequence to control for TAP-independent peptide presentation. Since neither T2 cells nor L929 cells (used as TAP-expressing control cells) express the K a or K b class I molecules that present, respectively, the P1 and P2 peptides to TcDs+, cells were coinfected with rVVs expressing antigenic peptides and rVVs expressing class I a chains. Presentation of P1 and P2 determinants was assessed in standard SlCr release assays using a secondary in vitro-stimulated splenocyte populations containing TcDs + specific for P1 or P2.
As seen in Fig. 1, A and B, in L929 cells, both P, and P2 determinants were liberated from S-P,P2 and S-P2P~, as well as from M-P1P2. The specificity of TCDS + recognition of these determinants is demonstrated by the reciprocal pattern of peptide specific lysis by TCDS+. The ability of L929 cells to present peptides from each of the rVVs tested provides functional demonstration of the integrity of the rVVs used to study presentation by T2 cells below.
TAP-deficient T2 cells (Fig. 1, C and D) demonstrated a more restricted pattern of presentation than L929 cells. Only the COOH-terminal determinant from either S-P1P2 or S-P2P1 was presented at similar levels to cells infected with rVVs expressing ER-inserted single determinants. Neither peptide was presented after infection with M-P1P2 which demonstrates that presentation of the S-tandem peptides in TAP-deficient cells is signal dependent. The ability of T2 cells to present P1 from S-P1 and P2 from S-P2 demonstrates that signal peptidase is perfectly capable of cleaving each of the antigenic peptides from the E3/19K signal sequence in an antigenic form. Thus, it is very likely that each of the tandem peptides is liberated from the signal sequence with its NH2 terminus intact. Most striking was the complete failure of T2 cells to present P2 from the S-P2P1 polypeptide. This finding was consistently reproduced in a large number of experiments. The presentation of the P1 determinant from S-PIP~ peptide at intermediate levels was routinely observed, indicating that secretory proteases demonstrate some capacity to liberate this peptide from its flanking sequences.
Peptide Trimming
Coexpression of K b and K a with precursor peptides in T2 cells did not alter the pattern of peptide presentation, since cells coinfected with VV-K d, VV-K b, VV-S-P1, and VV-S-P2 presented both determinants to TcDs § (Fig. 2) . This demonstrates that cells infected with even four rVVs express each foreign gene product at sufficient levels for TcDs + recognition, although the decreased levels of presentation likely stem from reduced expression of individual gene products.
Based on these findings, we conclude (a) that optimal processing of antigenic peptides from longer polypeptides within the secretory pathway entails that the determinant be located at the extreme COOH terminus; and (b) that this selective presentation of COOH-terminal peptides is not influenced by the presence or absence of a class I molecule able to bind the NH2-terminal peptide.
lntmcellular Localization of the Site of PeFtide Liberation. The dependence of peptide presentation on a NH2-terminal signal sequence demonstrates that proteolytic processing of the peptide occurs in the secretory pathway. To localize the site of proteolysis to the early (ER, c/s-Golgi network) or late (medial and trans-Golgi complex, post-Golgi transport vesicles) portions of the secretory pathway, we used a rVV expressing a Ka-molecule whose cytosolic domain was replaced with that of the E3/19K glycoprotein (17) . We previously reported that L929 cells coinfected with this rVV (termed VV-EClsK d) and an rVV expressing full-length NP do not present NP147q55 to TCDS+ (17) . HPLC purification of TFA-soluble peptides from these cells demonstrated that EC1sK a bound similar quantities of antigenic peptides as unmodified K a. Based on immunocytochemical and biochemical evidence, the poor efficiency of EC15K d presentation of NP147-155 can be attributed to its retention in the ER.
NP-specific TcDs + were unable to lyse T2 cells coinfected with VV-EC,sK d and either VV S-P2 or VV S-PIPz (not shown), demonstrating that EC15K d is also retained in the early secretory pathway of T2 cells. To determine whether intracellular EC15K d contained antigenic peptides, cells were homogenized in 0.1% TFA, and serial dilutions of unfractionated material of <3 kD were tested for ability to sensitize P815 cells (H-2 d) for lysis by P2-specific TCDS +. As seen in Fig. 3 A, recovery of antigenic peptide in acid extracts required the coexpression S-P1P2 and EC15K a, once again demonstrating the requirement of class I molecules in the recovery of antigenic peptides (16) . Similar amounts of peptides were recovered from cells expressing EClsK a and unmodified K d, indicating that retention of K d in the ER has little, if any, effect on the efficiency of peptide generation or association. Antigenic peptides extracted from EClsK a and K a were chromatographed by reverse-phase HPLC, and the fractions were tested for antigenic activity. Antigenically active peptides were recovered in a single peak that coeluted with a synthetic peptide corresponding to the P2 peptide, NP147-155 (Fig. 3 B) . This is consistent with the possibility that proteases in the early secretory pathway liberate the COOH-terminal nonamer from S-P1P2, but more precise chemical analysis of the antigenically active peptide is required to be certain that the peptide does not contain a few additional NH2-terminal residues.
Discussion
In the present study, we show that proteases present in the early secretory pathway contribute to the processing of peptides delivered to the ER in a signal sequence-dependent manner. It is striking that the COOH-terminal peptide is presented much more efficiently than the NH2-terminal peptide. This cannot be attributed to chemical differences between NH2-and COOH-terminal peptides, since similar patterns were observed with rVVs encoding reciprocal peptide precursors. The more efficient presentation of the COOHterminal determinant possibly reflects the critical nature of the interaction of COOH-terminal residues of antigenic peptides with class I molecules. The COOH-terminal residue serves as both an "anchor" residue whose side chain makes an important interaction with pockets in the class I molecule, and also provides critical binding energy through the interaction of main chain atoms with the binding groove. Extension of COOH termini by even a single residue often results in a drastic drop in peptide binding to class I molecules (16) . We favor the idea that some portion of the tandem peptide is tethered to class I molecules via its COOH terminus, while the NH2-terminal portion is trimmed by an aminopeptidase. The initial ligand might be the entire precursor peptide, or a fragment produced by endopeptidase activity.
The presence of endopeptidases in the early secretory pathway is consistent with the partial presentation of Pl from S-P1P2. The inefficient nature of this presentation might indicate a low level of endopeptidase cleavage of the precise PtP2 junction, or inefficient trimming of a longer peptide by carboxypeptidases. It is important to emphasize that the very large difference in efficiency of presentation of Pl and P2 by cells expressing S-P2P1 points very strongly towards the action of an aminopeptidase that creates the Pt peptide from either P1P2 or a COOH-terminal fragment of PtP2 created by endopeptidase activity.
Our findings implicating secretory aminopeptidases in antigen processing are, of course, limited to peptides delivered to the ER in a signal sequence-dependent manner. The possibility that these proteases can also contribute to the processing of TAP-transported peptides is, however, supported by recent findings regarding the specificity of TAP. Using a permeabilized cell system, TAP has been directly shown to transport peptides of up to at least 13 residues (7). Peptides of up to 30 or so residues have been recovered from a subset of HLA-B27 reactive with a specific mAb. The cell surface binding of this mAb to TAP-deficient cells was greatly reduced relative to TAP-expressing cells, suggesting that TAP is capable of transporting even very long peptides (23) . Findings using permeabilized cells or isolated microsomes indicate that TAP preferentially transports peptides with the types of COOH-terminal residues favored by class I molecules (5, 6) . Similarly, it has been reported that proteasomes (a multicatalytic cytosolic protease possibly involved in antigen processing) preferentially produce peptides with similar COOH termini, while cleavage at NH2 termini is much less selective (24) (25) (26) . These findings are consistent with the idea that many antigenie peptides are delivered to the EK with the proper COOH terminus, but with extensions at the NH2 terminus that can be removed by ER-aminopeptidases. Furthermore, these findings imply that the presence of a carboxypeptidase in the early secretory pathway might constitute a serious threat to antigenic peptides. Notably, a deficiency in EK carboxypeptidases is supported by our previous observation that expression of an exotic secreted carboxypeptidase is needed to facilitate presentation of a peptide extended by two residues from the natural COOH terminus (13) .
T2 cells efficiently produce antigenic peptides from HIV-I gp160, probably through the action of proteases located in an early secretory compartment (27) . The processing of intact membrane or secretory proteins in the ER of T2 cells would appear to be the exception rather than the rule, however, since neither integral membrane glycoproteins from measles (28) nor influenza viruses, nor ovalbumin, nor a secreted full-length form of influenza virus NP (our unpublished observations) is detectably processed in the secretory pathway of these cells. Perhaps the proteolytic processing of gp160 in T2 cells is initiated by the formation of aggregates of GP160 with CD4, which are disposed of by the Elk degradative system used to prevent the accumulation of defective proteins (29) . It will be of interest to examine the relationship between the proteases that contribute to the presentation of gp160 and our peptide precursors.
The identities of the secretory proteases involved in antigen processing remain to be established by biochemical methods. The possible involvement of dass I molecules in serving as a template for the appropriate proteases, or as a protease itself, as suggested in explanation for the dependence of class I molecules on the isolation of antigenic peptides from cells (30) , also remains as a subject of further investigation. The reagents described in this report should prove useful in the biochemical characterization of the secretory proteases involved in antigen processing.
